Correlation Between Adaptimmune Therapeutics and Alector

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Adaptimmune Therapeutics and Alector at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Adaptimmune Therapeutics and Alector into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Adaptimmune Therapeutics Plc and Alector, you can compare the effects of market volatilities on Adaptimmune Therapeutics and Alector and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Adaptimmune Therapeutics with a short position of Alector. Check out your portfolio center. Please also check ongoing floating volatility patterns of Adaptimmune Therapeutics and Alector.

Diversification Opportunities for Adaptimmune Therapeutics and Alector

0.49
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Adaptimmune and Alector is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Adaptimmune Therapeutics Plc and Alector in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alector and Adaptimmune Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Adaptimmune Therapeutics Plc are associated (or correlated) with Alector. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alector has no effect on the direction of Adaptimmune Therapeutics i.e., Adaptimmune Therapeutics and Alector go up and down completely randomly.

Pair Corralation between Adaptimmune Therapeutics and Alector

Given the investment horizon of 90 days Adaptimmune Therapeutics Plc is expected to generate 0.67 times more return on investment than Alector. However, Adaptimmune Therapeutics Plc is 1.49 times less risky than Alector. It trades about -0.16 of its potential returns per unit of risk. Alector is currently generating about -0.12 per unit of risk. If you would invest  127.00  in Adaptimmune Therapeutics Plc on August 30, 2024 and sell it today you would lose (54.00) from holding Adaptimmune Therapeutics Plc or give up 42.52% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Adaptimmune Therapeutics Plc  vs.  Alector

 Performance 
       Timeline  
Adaptimmune Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Alector 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Alector has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Adaptimmune Therapeutics and Alector Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Adaptimmune Therapeutics and Alector

The main advantage of trading using opposite Adaptimmune Therapeutics and Alector positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Adaptimmune Therapeutics position performs unexpectedly, Alector can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alector will offset losses from the drop in Alector's long position.
The idea behind Adaptimmune Therapeutics Plc and Alector pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Global Correlations
Find global opportunities by holding instruments from different markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
FinTech Suite
Use AI to screen and filter profitable investment opportunities